ImageneBio (IMA) Liabilities and Shareholders Equity (2020 - 2025)

ImageneBio has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $153.0 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 860.78% year-over-year to $153.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $570.9 million (up 15.28% YoY) and the FY2025 annual result came in at $153.0 million, up 860.78% from the prior year.
• Liabilities and Shareholders Equity slipped to $153.0 million in Q4 2025 per IMA's latest filing, from $160.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $293.7 million in Q1 2021 and troughed at $15.9 million in Q4 2024.
• A 5-year average of $184.1 million and a median of $172.5 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity plunged 91.71% in 2024, then soared 860.78% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $247.9 million in 2021, then slumped by 30.51% to $172.3 million in 2022, then increased by 11.51% to $192.1 million in 2023, then slumped by 91.71% to $15.9 million in 2024, then jumped by 860.78% to $153.0 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $153.0 million, $160.9 million, and $126.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.